Drug intelligence / Profile preview

ENOB-HV-11

Development stage: Preclinical
Lead developer: Renovaro
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

ENOB-HV-11 is an investigational preventive HIV vaccine candidate developed by Enochian BioSciences. The candidate is based on proprietary technology licensed from Weird Science and is currently undergoing preclinical evaluation in non-human primate (NHP) models, which are considered the gold standard for vaccine research. These studies are being conducted in collaboration with the Fred Hutchinson Cancer Research Center under the supervision of Dr. Hans-Peter Kiem, with additional support from the University of Pennsylvania. The program aims to establish a novel approach for the prevention of HIV infection by inducing a protective immune response.

Other names: ENOB-HV-11ENOB-HV11ENOB-HV 11

Beyond the preview

Go deeper on ENOB-HV-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENOB-HV-11.

Explore the full profile